Business context and reporting period
Champions Oncology, Inc. develops TumorGraft-based services to personalize cancer care and drug development. Its Personalized Oncology Solutions (POS) serves physicians and patients; Translational Oncology Solutions (TOS) serves pharmaceutical and biotechnology companies. This unaudited Form 10-Q covers the quarter and six months ended October 31, 2013. Unless noted, amounts below are in thousands of dollars.
Financial performance and position
| Metric | Three months ended Oct. 31, 2013 | Six months ended Oct. 31, 2013 |
|---|---|---|
| Revenue | $2,383; +63.4% year over year | $5,403; +51.6% |
| Operating loss | $(1,701), versus $(1,916) | $(2,472), versus $(3,516) |
| Net loss | $(2,318), versus $(1,974) | $(4,556), versus $(3,297) |
| Net loss per share | $(0.03), versus $(0.04) | $(0.07), unchanged |
| Operating cash used | Not provided separately | $(1,902), versus $(2,554) |
Quarterly revenue grew in both businesses: POS was $623 (+35.7%) and TOS was $1,760 (+76.2%). For the six months, POS revenue declined 9.6% to $1,245, while TOS revenue rose 90.1% to $4,158. TOS gross margin was 60% for the quarter and 62% for the six months, compared with 53% and 46%, respectively, a year earlier. POS gross margin was (17.5)% for the quarter versus (26.8)%; for the six months it was (22.5)% versus 1.7%.
At October 31, cash and cash equivalents were $7,572, down from $9,561 at April 30; working capital was $6.0 million. Total assets were $10,502 and total liabilities were $6,363, including a $3,094 warrant liability. The filing reports no off-balance-sheet debt or similar obligations; it does not present a conventional debt balance. Stockholders’ deficit was $12,743, alongside $16,882 of redeemable common stock. Cash used in investing was $76, primarily for equipment; financing provided $9 from option exercises.
Changes, outlook, risks and unusual items
- Revenue growth was led by TOS and new and existing customers. Management attributed the six-month POS decline to lower sales of non-core tumor panels and gene sequencing, consistent with a strategy focused on TumorGraft implants and drug studies.
- Operating loss improved, but net loss increased for the six-month period. The main unusual factor was a $2,048 noncash warrant fair-value expense, driven primarily by the company’s share price; it increased the warrant liability from $1,046 at April 30 to $3,094 at October 31.
- Management said cash on hand was adequate to fund operations for at least the next 12 months, while warning that additional capital might be needed and could not be assured on acceptable terms. No specific financial guidance was provided.
- On December 6, 2013, after quarter-end, Pfizer agreed to pay $1,875,000 for a license to use part of the TumorGraft platform: $937,500 upon execution and the remainder upon successful delivery. The parties also plan to explore further development and research collaboration.
- Investors should note contingent redemption rights on certain private-placement shares upon a change of control or specified asset transaction; warrant anti-dilution provisions and related fair-value volatility; potential registration-default penalties, which the company said were not probable and had not been accrued; and dilution risk. After quarter-end, approximately 6.4 million options were granted at a weighted-average exercise price of $1.23.
- The company reported no material legal proceedings, no material changes to previously disclosed risk factors, and effective disclosure controls. It stated that it did not expect the Irinophore C development milestones to be achieved within the next 12 months.
Most important facts to verify
- Whether revenue growth, especially TOS growth, is sustainable and converts into cash.
- POS unit economics and whether its negative gross margin improves as internal laboratory efficiencies and volumes develop.
- Cash runway assumptions behind management’s 12-month liquidity statement, including working-capital needs and potential financing requirements.
- The valuation sensitivity and potential dilution or cash consequences of the warrant terms, redeemable shares, and subsequent option grants.
- Whether Pfizer’s contingent payment is recognized only upon the specified successful delivery, and the timing and conditions for collection.